Our findings not only demonstrated the therapeutic value of BRPF1 inhibitor in HCC treatment but also highlighted the emerging concept of targeting bromodomain-containing proteins as a new strategy for cancer treatment. The gene discussed is BRPF1; the disease is cancer.